Drug Information

Drug (ID: DG01443) and It's Reported Resistant Information

• Name: Tildrakizumab
• Indication:
  In total 1 Indication(s)
  Plaque psoriasis [ICD-11: EA90]; Approved; [1]
• Target: Interleukin-23 (IL23); IL23A_HUMAN; [1]
• Target: Interleukin-37 (IL37); IL37_HUMAN; [1]
• TTD Drug ID: D0FT3R

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-14: Skin diseases

Psoriasis [ICD-11: EA90]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Interleukin 23 receptor (IL23R) [1]

• Molecule Alteration: Function; Inhibition
• Sensitive Disease: Nail psoriasis [ICD-11: EA90.50]
• Experimental Note: Discovered Using In-vivo Testing Model
• Mechanism Description: Tildrakizumab, an IL-23 inhibitor, has shown significant clinical improvement in the treatment of moderate-to-severe chronic plaque psoriasis. We report 2 cases of treatment resistant nail psoriasis which showed marked improvement with the use of off-label tildrakizumab.

References

• Ref 1: Successful management of treatment resistant nail psoriasis with tildrakizumab .Australas J Dermatol. 2021 Aug;62(3):390-393. doi: 10.1111/ajd.13642. Epub 2021 Jun 11. 10.1111/ajd.13642